Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd Global Summit on Oncology & Cancer Tokyo, Japan.

Submit your Abstract
or e-mail to

globalcancer@cancermeet.org
globalcancer@conferencesseries.org
asiaevents@conferenceseries.com

Scientific Program Day 1
Scientific Program Day 2

Day 2 :

Keynote Forum

Kunal Sharma

SRL Diagnostics, India

Keynote: Advances in diagnostics in lung cancer

Time : 10:00-10:40

Conference Series Global Cancer 2019 International Conference Keynote Speaker Kunal Sharma photo
Biography:

Kunal Sharma is currently working as a Consultant Oncopathologist, Molecular Pathologist & Section Head with SRL Diagnostics, India. He was in past working as Consultant Oncopathologist & Head of Quality Assurance at CORE Diagnostics Pvt. Ltd. He has been a guest faculty & presenter at numerous international and national conferences like Lymphoma & Myeloma Congress- New York, CAP-Chicago, The International Society of Paediatric Oncology (SIOP), Nigerian Medical Association, Dhaka Medical College & Bangladesh association of Hematologists, Indian Cancer Congress, ISMPOCON, YROC, ONCOCON etc. He was the faculty & mentor of the largest National hands on IHC workshop (D-I-Y) at JNMC, Belgavi. He has numerous international publications including first reported case of Cellular Ovarian Fibroma in India. He completed his MBBS with aggregate of 73% and received his Post-graduate training (DNB) in Oncopathology from HCG Cancer Hospital, Bangalore
 

Abstract:

Lung cancer remains the leading cause of cancer related deaths in most countries. Most (but not all) lung cancers are associated with tobacco smoking. Up until recent times, the diagnosis was in most cases based on histology and use of immunohistochemistry to classify lung epithelial tumors into small cell vs non- small cell (squamous and adeno) carcinomas. With the advent of better understanding of the biology of lung cancer, especially underlying oncogenic driver mutations, the hunt to develop targets to these mutations has increased manifold. This has led to the discovery of actionable mutations like EGFR, ALK and ROS-1. Current guidelines include testing for these driver mutations, aided primarily by clinical presentation and the histological subtype of tumor. There has also been a prominent focus on liquid biopsies in lung cancer given their innumerable advantages. We have thus witnessed a consequential change in the approach to treatment and survival of these patients. From an average survival of 2-4 months in 1990s, introduction of platinum-based combinations with third-generation agents and more specific cytotoxic drugs, significantly improved survival outcomes to 1-2 years. The newly developed targeted therapy in the appropriate patient population, may provide greater benefit than conventional chemotherapy and may further improve the survival rates in these patients. 

  • Precision Cancer Medicine & Oncology | Organ-Defined Cancers| Cancer Pharmacology | Cancer Awareness and Survival
Location: Meeting Room 1
Speaker

Chair

Kunal Sharma

SRL Diagnostics, India

Session Introduction

Paulus S Wang

National Yang-Ming University, Taiwan

Title: Effect of prolactin on cell proliferation in non-small cell lung cancer cells

Time : 10:40-11:10

Speaker
Biography:

Paulus S Wang worked as a Professor at the Department of Physiology, National Yang-Ming University (NYMU). He is currently working as a Chair-Professor and also the Director in the Medical Center of Aging Research, China Medical University Hospital (CMUH) and also Founder of both the Society of Adaptive Science in Taiwan (SAST) and also the Taiwan Society of Endocrinology and Metabolism (TSEM).
pswang3879

Abstract:

It has been known that the concentration of Serum Prolactin (PRL) in lung cancer patients is higher than in healthy people. Recent reports point out that the PRL expression level of lung cancer tissues is related to patient’s survival rate. The lower survival rate occurs in patients who have higher PRL expression level. The aim of this study was to investigate the stimulatory mechanism of PRL in non-small cell lung cancer cells. We detected the effect of PRL on cell proliferation by MTT assay. The results show that cell proliferation was significantly increased after treatment with PRL by 50 nm for 24 hours. We also detected cell proliferation related signaling pathway JAK2/STAT3 and EMT (Epithelial–mesenchymal transition) marker by western blot. The protein levels of p-JAK2 and p-STAT3 were significantly increased after treatment with PRL. We also analyzed STAT3 regulated downstream gene VEGF mRNA level and protein level by qRT-PCR and western blot. VEGF mRNA and protein levels were significantly increased by PRL. The protein expressions of p-JAK2, p-STAT3 and VEGF were inhibited by JAK2 inhibitor AZD1480. AZD1480 treatment also led reduction of cell proliferation. Not only cell proliferation but also metastasis was led low survival rate in lung cancer patients. Results show that PRL also enhanced the protein levels of N-cadherin and vimentin. The protein expression of E-cadherin was decreased after treatment with PRL. We can conclude that these results suggested that PRL might promote NSCLC cells cell proliferation which was regulated through JAK2/STAT3 signaling pathway and EMT.

Joshua K S Ko

Hong Kong Baptist University, China

Title: Therapeutic potential of henryin in the treatment of pancreatic cancer

Time : 11:30-12:00

Speaker
Biography:

Joshua K S Ko obtained his PhD degree in Pharmacology at the University of Hong Kong Medical School after completion of his undergraduate training at the University of Toronto, Canada with double specialists in Toxicology and Nutritional Sciences. He has been actively involved in many research projects, published over 100 papers in reputed journals and serving as an editorial board member of various journals including those of the Nature Publishing Group. He is currently member of the American Association for Cancer Research (AACR), European Association for Cancer Research (EACR) and International Union of Basic and Clinical Pharmacology (IUPHAR).
 

Abstract:

Pancreatic cancer is characterized by early metastasis and poor prognosis. Henryin, an Isodon diterpenoid, was suggested to exhibit anti-carcinogenic activity. For the first time, we have unveiled its anticancer potential in pancreatic cancer cells. Our results have shown that henryin (0.1-10 μM) induced growth inhibition in PANC-1 pancreatic cancer cells, which was most significant among other cancer cell types. The growth-inhibitory effect of henryin was more prominent among other ent-kaurane diterpenoids under the same dose range. Besides, it has also been noted that henryin reduced the number and size of cancer cell colonies and facilitated both autophagy and apoptotic cell death. The drug action of henryin (1 or 5 μM) in combination with the orthodox chemotherapeutic drug gemcitabine (10-500 nM) were also studied. Data indicate synergistic effects of henryin and gemcitabine on cell growth inhibition as proven by isobologram analysis. Following the tests on a combination of henryin-gemcitabine working concentrations, the optimal effect on the induction of apoptosis was found to be 1 μM of henryin and 100 nM of gemicitabine, even better than the use of gemcitabine at a higher concentration of 250 nM. Other than this, the henryin-gemcitabine combo also induced S-phase cell cycle arrest. S100A4 plays an important role in cancer invasion and metastasis. Our data here have revealed that henryin suppressed rS100A4-mediated migration of PANC1 cells through downregulation of pro-invasive and angiogenic factors. Findings in this study have exemplified that henryin could is a drug adjuvant that concomitantly increases the effectiveness of pancreatic cancer chemotherapic drugs.
 

Vinay Sharma

University of Witwatersrand, South Africa

Title: Conformal radiation therapy for breast cancer

Time : 12:00-12:30

Speaker
Biography:

Vinay Sharma is currently working as Head of Department of Radiation Oncology at Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand. He has published over 150 papers in in national and international peer reviewed journals as well as book chapters. His main research interest is in breast cancers as well as gynecological malignancies

Abstract:

Conformal radiation therapy for breast cancer is being used as a standard radiation therapy technique in most centers in the world. The aim of the study was to document the doses to lung and heart (organs at risk) in addition to breast tumor volumes to correlate with treatment related toxicities. A total of 115 patients of cancer of breast underwent CT scans and planning procedure after decision at the multidisciplinary management meeting during 2016-17. Both right and left breast were almost equally affected right 62 patients (54%) and left 53 patients (46%). All patients had MUGA scans before RT planning. 43 patients (37%) had conservative breast surgery and 72 had mastectomies. 74 patients (64%) received 50 Gy in 25 fractions and 39 (34%) patients had 40.05 Gy in 15 fractions. The radiation therapy was delivered using 6 Mv photos with different fields. The patients with conservative surgery received a boost to the tumor bed following tangential field. The patients with locally advanced disease and nodal involvement received radiation to chest wall as well lymph drainage areas. 48% (56 patients) had radiation to chest wall and lymph drainage areas; 30 patients (26%) had tangential field and tumor bed boost. The lung constraints used were V20=≤30Gy, V8=35-40% and mean lung dose=<15 Gy. 106 patients (92%) achieved the lung constraints. The heart constraints used were V25 Gy=<10% and mean heart dose=<26 Gy. The heart constraints could be achieved in all except one patient both V25 as well as mean heart dose. Conformal radiation was able to achieve the aim of study and constraints were maintained in over 90 percent patients. There is no toxicity reported up till now on follow up and is increasingly being practiced.
 

Marilyn Parkin

International College of Medical Intuition, Canada Lunch Break

Title: Bio-Physical tendencies with applied methods of mind/body/soul techniques sound frequencies and including the art of intuition

Time : 12:30-13:00

Speaker
Biography:

Parkin has been a practicing Medical Intuitive for several years. She earned her PhD in Energy Medicine through an innovative program designed by Dr. Norm Shealy and Dr. Caroline Myss. Dr. Parkin previously spent many years in nursing and holds a degree in Sociology and Psychology. She also teaches Health and Empowerment seminars worldwide and has founded the International College of Medical Intuition, Inc (2002) which has locations in Hawaii, Vancouver and NY.
 

Abstract:

The study was conducted to determine the effects of sound vibration on individuals with depression. The study also examined changes to the blood cell after the intervention of vibratory frequencies ranging from 120Hz to 10Hz throughout the magnetic field of the body. Variables introduced were time frame of one hour of control group listening to music and experimental group positioned on a sound vibrational treatment table to absorb the music vibrations. The random study was conducted on 60 subjects with inclusion of 25 to 45 years of age and >6 months maintenance dose of antidepressant drug, Paxil. Measurement was accomplished through evaluation of Live Blood Analysis and Hamilton Rating Scale for Depression. A blood draw process of Live Blood Analysis was obtained and examined for specific quality and level of visible clumping. Post blood analysis determined less clumping and healthier activity of the cell after intervention in the experimental group. The Live Blood Analysis of the control group remained unchanged. Hamilton Rating Scale for Depression indicated decreased levels of depression in experimental group. Hypothesis supports changes toward healthier cellular activity and appearance of less blood cell clumping and decreased level of depression with increased levels of frequency through sound vibrational treatment table. Application of this model has been applied within informal studies and observations on adults and children for various conditions with similar results.
 

Ola Osama Ahmed Hafez

Cairo University, Egypt

Title: Management and outcome of breast cancer patients with ipsilateral supraclavicular lymph nodes involvement at presentation retrospective study

Time : 14:00-14:30

Speaker
Biography:

Ola Osama Ahmed Hafe is an Egyptian. He is a Physician young Oncology Specialist in Helwan University. He has completed his Master’s degree from Kasr Al Ainy School of Oncology, Cairo University. He is currently working as Specialist in governmental and private oncology centers. He is interested in research as well as clinical practice.
 

Abstract:

Breast cancer is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. About 4% have had ipsilateral Supraclavicular Lymph Nodes involvement (SCLNs). In spite this very low incidence, a big conflict occur in TNM staging and management. The current study was a retro prospective observational descriptive study. We re¬viewed the files of breast cancer patients with synchronized with ipsilateral SCLNs involvement without distant metastasis that were seen in the follow up clinic in the period (Feb 2016-August 2016) at NEMROCK oncology Department, Kasr Al Ainy School of Medicine. Clinic pathological data was described for 34 patients as age (median 50.5 years), menopausal status (pre-menopause were 47.1%), family history (positive in 23.5%), site of tumor (UOQ 67.6 %), side (Rt 52.9 %), hormonal receptors (positive in 58.8%), initial T (T3 and T4 70.6%). Treatment applied NAC was given to 73.5% and the response was regressive in 44% of patients, 64.7 % underwent mastectomy while 14.7 % gone for conservation, 41.1 % received adjuvant hormonal treatment, post-treatment pathological T (3,4) was 35.3 %. Local recurrence occur in 14.7%, systemic relapse occur in17.6%. We don't comment on overall survival because of selection bias. Although the incidence of patients with breast cancer who present with ipsilateral SCLNs involvement without distant spread at time of diagnosis is low. It seems reasonable to consider this selective patient group as a loco regional and thereby a potentially curable disease and should be treated with a curative rather than palliative intent. Nevertheless, one should keep in mind that patients presenting with supraclavicular disease are at high risk for harboring distant metastatic disease, even when clinically detectable metastases are not evident. Patients should be offered a combined-modality approach, including systemic therapy, surgery and radiotherapy.